Hisamitsu Pharmaceutical FY2026 Analysis: Revenue Growth Masks Profit Pressure Amid Cost Challenges
Hisamitsu Pharmaceutical Co., Inc. (久光製薬株式会社) (TSE:4530) reported full-year fiscal 2026 results showing continued revenue growth, but declining operating and net profits, reflecting rising cost pressures and margin compression. The company, a leader in Japan’s over-the-counter (OTC) pharmaceutical market with its flagship product Salonpas, is expanding its presence in international markets such as the U.S. and China.
Key Numbers (JPY bn)
| Metric | FY2026 (JPY bn) | FY2025 (JPY bn) | YoY Change |
|---|---|---|---|
| Revenue | 163.0 | 156.0 | +4.5% |
| Operating Profit | 17.9 | 18.9 | -5.2% |
| Ordinary Income | 24.0 | 24.0 | -0.2% |
| Net Profit | 19.2 | 21.8 | -11.9% |
| Operating Margin | 11.0% | — | — |
| Equity Ratio | 79.4% | 80.6% | — |
Business Overview
Hisamitsu Pharmaceutical is a major player in Japan’s OTC pharmaceutical sector, best known for its pain-relief patch product Salonpas. The company is actively expanding its global footprint, particularly in the U.S. and China, while also focusing on innovation in medical technologies such as microneedle delivery systems.
Analysis
Hisamitsu Pharmaceutical’s revenue increased by 4.5% year-over-year, driven by strong sales of its core products and continued international expansion. However, the company’s operating profit declined by 5.2%, indicating that revenue growth has not been matched by proportional improvements in profitability. This margin compression is likely due to rising input costs, increased promotional expenses, and intensified competition in key markets.
Ordinary income, which includes operating profit plus non-operating income and expenses such as interest and investment gains, fell slightly by 0.2%, while net profit dropped by 11.9% year-over-year. The significant decline in net profit suggests the impact of non-operating expenses, higher tax burdens, or increased investment-related costs. The company’s equity ratio also decreased by 1.2 percentage points, indicating a shift in its capital structure, potentially due to increased debt or reduced retained earnings.
Despite the profit challenges, Hisamitsu Pharmaceutical’s operating margin of 11.0% remains well above the industry average of 6.0%, highlighting its strong cost management and pricing power in its core markets. However, the company will need to address margin pressures to sustain long-term profitability.
Next Year Guidance
Management has not disclosed guidance for the next fiscal year at this stage.
What to Watch
- Cost Management and Margin Recovery: The company will need to imp